Ligand Pharmaceuticals Incorporated

DB:LGDN Stock Report

Market Cap: €1.9b

Ligand Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?


Recent Insider Transactions

DB:LGDN Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
04 Mar 25Sell€546,161Octavio EspinozaIndividual5,000€109.23
23 Dec 24Sell€235,497Octavio EspinozaIndividual2,104€111.93
20 Sep 24Sell€120,847Matthew KorenbergIndividual1,293€93.46
20 Sep 24Sell€118,975Octavio EspinozaIndividual1,275€93.35
26 Aug 24Sell€1,778,839Matthew KorenbergIndividual18,858€95.21
09 Aug 24Sell€1,644,915Matthew KorenbergIndividual18,245€90.16
08 Aug 24Buy€223,174Todd DavisIndividual2,500€89.27
16 May 24Sell€643,871Octavio EspinozaIndividual8,137€79.13
14 May 24Sell€1,382,663Matthew KorenbergIndividual17,598€79.21
09 May 24Sell€72,126Nancy GrayIndividual934€77.22

Insider Trading Volume

Insider Buying: LGDN insiders have only sold shares in the past 3 months.


Ownership Breakdown

What is the ownership structure of LGDN?
Owner TypeNumber of SharesOwnership Percentage
State or Government5,4860.0285%
General Public102,7110.533%
Individual Insiders406,3162.11%
Institutions18,740,84097.3%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Top 25 shareholders own 74.46% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
15.3%
BlackRock, Inc.
2,946,084€295.9m-1.79%no data
10.8%
The Vanguard Group, Inc.
2,085,627€209.5m5.84%no data
5.27%
Janus Henderson Group plc
1,015,023€101.9m0.59%0.04%
4.59%
Macquarie Investment Management Business Trust
884,380€88.8m-0.33%0.12%
3.86%
State Street Global Advisors, Inc.
743,632€74.7m5.12%no data
3.75%
Dimensional Fund Advisors LP
723,019€72.6m2.26%0.01%
3.23%
Congress Asset Management Company, LLP
621,482€62.4m2.89%0.48%
3.18%
Stephens Investment Management Group, LLC
612,782€61.5m-0.96%0.95%
2.86%
Chicago Capital, LLC
551,588€55.4m1.06%1.63%
2.28%
Geode Capital Management, LLC
438,441€44.0m2.37%no data
2.07%
Loomis Sayles & Company, L.P.
397,700€39.9m6.69%0.06%
1.61%
Ashford Capital Management Inc
310,664€31.2m0.08%4.03%
1.58%
Rice Hall James & Associates, LLC
304,925€30.6m-2.54%1.9%
1.5%
Deutsche Asset & Wealth Management
289,052€29.0m5.54%0.01%
1.49%
St. Denis J. Villere & Co., LLC
287,044€28.8m-39.5%2.96%
1.47%
Northern Trust Global Investments
282,957€28.4m7.69%no data
1.46%
Impax Asset Management Group Plc
280,208€28.1m0%0.09%
1.44%
Massachusetts Financial Services Company
276,731€27.8m0%0.01%
1.42%
DWS Investment Management Americas, Inc.
273,976€27.5m0%0.13%
0.96%
Franklin Resources, Inc.
184,971€18.6m96.2%0.01%
0.94%
Invesco Capital Management LLC
181,552€18.2m2.71%0.01%
0.92%
Aberdeen Group Plc
176,760€17.8m-29.1%0.01%
0.89%
Charles Schwab Investment Management, Inc.
170,419€17.1m3.96%no data
0.85%
Driehaus Capital Management LLC
162,771€16.3m70%0.11%
0.7%
Kornitzer Capital Management, Inc.
135,482€13.6m0%0.26%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/18 12:31
End of Day Share Price 2025/03/18 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Ligand Pharmaceuticals Incorporated is covered by 22 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jasper HellwegArgus Research Company
Balaji PrasadBarclays
Balaji PrasadBarclays